Germany | Bayern

Zurück zur Suche

Internationale Partnersuche

Innovation & Technologie Angebot

Molecular oncology diagnostic tool in targeted therapy

Country of Origin: Italy
Reference Number: TOIT20190524001
Publication Date: 30 May 2019

Summary

Italian biotech spin-off company working in the oncology field,  integrated with clinical activities of a research institute, offers a broad range of diagnostic tool, from molecular diagnostic to pathology and cytofluorimetry. The methodology is aimed to the diagnostic needs of clinicians and laboratories. Biotech, pharmaceutical and research companies are sought for joint venture and/or research cooperation agreements.

Description

The Italian company offers a full range of histology and cytology tests for oncology.  Stemming from the clinical experience the molecular tests are based on the choice of the most important genes involved in the targeted therapy and differential diagnostics. They are available either as single-test format, or in panel based on Next Generation Sequencing (NGS), targeted for differential clinical needs. The test can be combined in a customized format providing a flexible and broad menu covering all the currently actionable molecular signatures. A constant update of new drugs/diagnostics development is a major focus of the approach proposed. It allows to immediately exploit the most advanced therapeutic and diagnostic opportunities. 
The diagnostic branch of research centre, strictly integrated with the clinical activities, offers a broad range of diagnostic tests in the fields of oncology such as gynecological tumors. Its engagement in the front-edge research projects paves the way for catching new opportunities in diagnostic, and making them available to the clinics.
The Precision Medicine world is a reality in everyday patient management. This new paradigm implies new challenge and efforts to make this emerging diagnostics services really user-friendly, cost-effective and quick in delivery of results. Most important for exploiting the full potential of personalized medicine is the correct classification and characterization of samples, and, in oncohematology, the featuring of phenotypic markers for differential diagnosis and patient monitoring.
The molecular analysis are systematically integrate with careful evaluation and validation of the samples, for the subsequent correct analysis of the molecular signatures of the tumor.
The Italian company is seeking biotech, pharmaceutical and diagnostic companies interested in clinical trials expertise, diagnostics development, new therapeutic tools for joint venture agreements.
An example of application is gynecological tumors which represent heavy burden to female patients, the detection and typing HPV (Human Papilloma Virus) for the identification of agents, control screening and diagnosis.
The company is also looking for research cooperation for participating in European calls for proposal.
Image

Advantages and Innovations

The advantages are based on the selection of the most important genes in the targeted therapy an differentia diagnostic, consequently 
--personalized medicine;
--therapy Monitoring;
--customized format.
The diagnostic tool is based on unique innovative expertise aimed to offer a complete, scientifically and technically assistance to the partners involved in this rapidly evolving fields.

Stage Of Development

Already on the market

Requested partner

The Italian company is seeking biotech, pharmaceutical and diagnostic companies interested for joint venture agreements, involving in clinical trials expertise, diagnostics  development, interested to acquire the new therapeutic tool proposed.
E.g. gynecologist for the detection and typing HPV (Human Papilloma Virus) for detection agents relevant in female health control screening and diagnosis.

The company is also looking for R&D institutions for participating in European calls for proposal.

Kooperationsanfrage stellen